Navigation Links
InNexus Biotechnology Completes Preclinical Study Confirming in Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting With FDA
Date:1/13/2009

BRITISH COLUMBIA, Canada, Jan. 13 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the completion of a large scale primate study confirming effectiveness and safety of its lead candidate DXL625 (CD20). The Company also announced that it has scheduled a meeting with the United States Food and Drug Administration (FDA) during the first half of 2009 to discuss the design of a clinical study.

"This study confirms that DXL625 is specific to the CD20 antigen present on NHL tumor cells and is a major milestone in our plan for clinical and commercial success," said Jeff Morhet, CEO and Chairman of InNexus. "This success paves the way for the filing of an IND and commencement of clinical trials of DXL625 in the near future." Complete results from this study are being compiled and will be presented at the annual scientific meeting of the American Association for Cancer Research (AACR) this spring.

InNexus' recently completed study was designed to confirm DXL625's in vivo safety and efficacy. The candidate was effective in completely eliminating all lymphocytes with a CD20 marker within hours at the lowest dose tested. No adverse events were seen even at a dose 100-fold higher than the lowest dose. The CD20 marker is the same as that found on tumors cells in patients with Non-Hodgkins Lymphoma patients. Previous studies have shown that DXL625 has greater potency as compared to existing therapeutic antibodies.

Pre-clinical data show that DXL625 has a safety profile equal to Rituxan(R) when evaluated in the same validated model. The preclinical study was conducted with a single injection, which confirms the remarkable potency
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
2. Accuray Incorporated Ranked Fifth in Deloittes Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies
3. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
4. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
5. CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
6. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
7. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
9. BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
10. Genetic Engineering and Biotechnology News reports on early ADMET use
11. China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 Supply & ... annual listing of “Pros to Know” in the supply ... two members of MEBC’s leadership team were included on ... nominated and received this award due to their hard ... innovative methods for meeting and resolving client needs and ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
(Date:3/5/2015)... March 05, 2015 Wimbledon Health ... provides vascular, echocardiogram and NCV testing, announced ... the Chief Medical Officer. Dr. Artel will be responsible ... of the WimbledonMED program and the continued growth and ... about working with Wimbledon Health Partners as a consulting ...
(Date:3/5/2015)... March 05, 2015 March 5, 2015 ... off next week (March 8-14, 2015), children’s hospitals around ... play in making hospital stays as safe as possible ... children’s hospitals—Children’s Hospitals’ Solutions for Patient Safety (SPS) and ... for families to follow when visiting the hospital with ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4
... at the chemical plan in the month of November released toxic ... in Russia also as they share the same water resources. // ... the danger of concentration of these chemicals due to the melting ... test to be carried out in a random fashion to make ...
... the moles which are seen among elderly Australians who run ... dangerous. // The country’s skin specialists believe that this is ... many as 309 patients were studied during the course of ... of the new moles on older patients being melanomas were ...
... a very low calories diet can help the heart age more ... to be the first ever human trial study. // ... demonstrate the cardiac benefits of a restricted calorie diet. ... the Caloric Restriction Society, ages 41 to 64, who consume 1,400 ...
... not feel threatened by the bird flu outbreaks in Turkey, ... reported to have already taken measures// to prevent the spread ... ready to face all possibilities of an outbreak. The Government ... virus. ,Money has already been apportioned by ...
... U.S. Army Medical Research Institute of Infectious Diseases have found ... protection and treatment of humans // from wild strains of ... has to be done as this Ebola virus offers a ... are published in the Journal Public Library of Science Pathogens. ...
... doctors it is imperative that global guidelines for giving iron ... The reason is// that since they might be dangerous ... by researchers from the United States and Tanzania. They called ... severe illness and death if they are given to children ...
Cached Medicine News:Health News:UN Fears Melting Of Ice Would Concentrate Toxins in the Chinese Water Supply 2
(Date:3/5/2015)... March 5, 2015  Relmada Therapeutics, Inc. (OTCQB: ... the treatment of chronic pain, today announced the ... advisory roles. The panel of experts will provide ... efforts to advance the company pipeline of novel ... expertise in a range of areas including opioid ...
(Date:3/5/2015)... 2015 LUNGevity Foundation, the nation,s leading ... Administration,s (FDA) approval of Bristol Myers Squibb,s new ... treatments add another critical new treatment option to ... a patient,s own immune system to fight cancerous ... for patients with squamous cell lung cancer, a ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Japan Pharma Outlook 2015: Year to Watch ... Initiatives" report to their offering. ... from April -2014 (Annexure 1) is a ... - whether generic or innovator. The most of the ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3
... 2011 Reportlinker.com announces that a new ... catalogue: Pharmaceutical Key Trends ... the pharmaceutical industry ... A number of factors have ...
... Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced ... Administration,s (the "FDA") Division of Oncology Drug Products (the ... New Drug Application (the "NDA") for pixantrone for relapsed ... for accelerated approval based on the PIX301 study results. ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry 2Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry 3Reportlinker Adds Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry 4Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval 2Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval 3Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: